You are watching a 25-second preview. Log in or Register to keep watching.

Your 25-second preview has ended.

To continue watching, please Log in or Register.

Log In / Register

Implementing CXL in Your Practice

Show Description +

In this roundtable discussion, Richard L. Lindstrom, MD; Brandon D. Ayres, MD; Kathryn M. Hatch, MD; Rajesh K. Rajpal, MD; and Sara B. Rapuano, MBA, CPC, COE, OCS, touch on the approval of CXL in the US, what it takes to incorporate CXL into your practice, and the benefits of using an FDA-approved procedure. They also discuss the Avedro Reimbursement Customer Hub (ARCH) Program.

Posted: 3/21/2019

Up Next

CXL Co-Management & Clinical Pearls

Brandon D. Ayres, MD, Kathryn M. Hatch, MD, Rajesh K. Rajpal, MD, Richard L. Lindstrom MD, Sara B. Rapuano, MBA, CPC, COE, OCS


CXL and Reimbursement - How the Process Works

Allison W. Shuren, MSN, JD, Rajesh K. Rajpal, MD, Sara B. Rapuano, MBA, CPC, COE, OCS

What It Takes to Implement Cross-Linking and Insurance In Your Practice

Brandon D. Ayres, MD, Kathryn M. Hatch, MD, Rajesh K. Rajpal, MD, Richard L. Lindstrom MD, Sara B. Rapuano, MBA, CPC, COE, OCS

Cross-Linking Complex Cases

Kathryn M. Hatch, MD

Implementing CXL in Your Practice

In this roundtable discussion, Richard L. Lindstrom, MD; Brandon D. Ayres, MD; Kathryn M. Hatch, MD; Rajesh K. Rajpal, MD; and Sara B. Rapuano, MBA, CPC, COE, OCS, touch on the approval of CXL in the US, what it takes to incorporate CXL into your practice, and the benefits of using an FDA-approved procedure. They also discuss the Avedro Reimbursement Customer Hub (ARCH) Program.

Posted: 3/21/2019

Resources

Nuts and Bolts of Implementing Corneal Cross-linking in Your Practice

View Supplement

CXL And Insurance: A How-To Guide

View Supplement

Cross-Linking Reimbursement: A Case Study In How The Process Works

View Supplement

Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

View Brochure

Keratoconus and Corneal Cross-Linking: Information for Diagnosing Providers

View Brochure

Living with Keratonconus

View Patient Brochure

Avedro Reimbursement Customer Hub

View Hub

CXL Co-Management and Clinical Pearls

View Supplement

IMPORTANT SAFETY INFORMATION

INDICATIONS

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking (CXL) for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

LIMITATIONS OF USE

The safety and effectiveness of CXL has not been established in pregnant women, women who are breastfeeding, patients who are less than 14 years of age and patients 65 years of age or older. Photrexa Viscous and Photrexa should be used with the KXL System only.

WARNINGS AND PRECAUTIONS

Ulcerative keratitis can occur. Patients should be monitored for resolution of epithelial defects.

ADVERSE REACTIONS

In progressive keratoconus patients, the most common ocular adverse reactions in any CXL treated eye were corneal opacity (haze), punctate keratitis, corneal striae, corneal epithelium defect, eye pain, reduced visual acuity, and blurred vision. In corneal ectasia patients, the most common ocular adverse reactions were corneal opacity (haze), corneal epithelium defect, corneal striae, dry eye, eye pain, punctate keratitis, photophobia, reduced visual acuity, and blurred vision.

These are not all of the side effects of Photrexa® Viscous, Photrexa® and the CXL treatment. For more information, see Prescribing Information. You may report an adverse event to Avedro by calling 1-844-528-3376, Option 1 or you may contact the U.S. Food and Drug Administration (FDA) directly at 1-800-FDA-1088.